India, Nov. 16 -- CapsoVision Inc. (CV), a commercial-stage medical technology company, released financial results for the third quarter, noting a narrowed net loss as expenses declined.
The company operates as a provider of AI-powered detection solutions for gastrointestinal diseases, particularly through its flagship product, CapsoCam Plus. CapsoCam consists of a high-resolution, wire-free endoscope used to visualize the small bowel. CapsoCam Colon is under development for non-invasive colon imaging and polyp screening using enhanced AI.
Q3 Financial Results:
Net loss for the third quarter came to $7.34 million or $0.15 per share, marking a slight narrowing from the $7.92 million or $0.14 per share recorded in the same period of 2025....